ArticleDiscover oncology2025
Research of SLC7A11 to estimate the prognosis and immune infiltration landscape for breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapy as a State-Generator: Dynamic Phenotypic Landscapes and Adaptive Stress Circuits in Chemotherapy Resistance of Breast Cancer.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
SLC7A11, a key factor protecting cancer cells from oxidative stress, is upregulated and shows prognostic significance in amounts of malignant tumors largely while its role still remains indistinct in breast cancer. We conduct an explicit analysis of the gene SLC7A11 based on The Cancer Genome Atlas (TCGA) for breast cancer patients. Subsequently the co-expressed genes of SLC7A11 are identified. On account of the previous exploration of SLC7A11 thoroughly, we assess the immune infiltrating cell populations and immune checkpoints in breast cancer to unveil the complexity of tumor microenvironment (TME) by Cibersort and Tumor Infiltrating Estimation Resources (TIMER). We continue to conduct a further preliminary investigation into the drug resistance of breast cancer. Compared to the normal tissue, SLC7A11 is significantly expressed in breast cancer, and its differential expression is evident in patients without distant metastasis (M0). Elevated expression of SLC7A11 is associated with notable changes in the tumor microenvironment (TME) for breast cancer patients, including a decreased presence of CD8 + T cells and activated natural killer (NK) cells. Additionally, there is an increase in immune checkpoint such as CD274, CTLA4, HAVCR2, LAG3, PDCD1LG2 and TIGIT. This modulation in the immune landscape corresponds with improved sensitivity to conventional breast cancer treatments. Our comprehensive analysis confirms that SLC7A11 is a dependable tumor biomarker, offering valuable insights for the development of targeted therapies in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.